Screening for prostate cancer: the current evidence and guidelines controversy.
暂无分享,去创建一个
A. Dicker | T. Showalter | R. Wender | R. Myers | E. Trabulsi | L. Gomella | Xiaolong S. Liu | W. Kelly | X. Liu
[1] M. Safarinejad. Prostate cancer screening: yes or no? , 2013, Urology journal.
[2] P. Gøtzsche,et al. Screening for breast cancer with mammography , 2013, medRxiv.
[3] V. Moyer. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[4] A. Jemal,et al. Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[5] Dan Stoianovici,et al. Advancements in MR imaging of the prostate: from diagnosis to interventions. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[6] Fredrik Wiklund,et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer , 2011, The Prostate.
[7] A. Partin,et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. D'Amico,et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Metter,et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Halpern,et al. Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer. , 2010, Urology.
[11] H. Yasunaga,et al. Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010 , 2010, International journal of urology : official journal of the Japanese Urological Association.
[12] R. Piana. Mortality results from the Göteborg prostate-cancer screening trial , 2010 .
[13] P. Prorok,et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2010, Clinical trials.
[14] E. Steyerberg,et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC , 2010, International journal of cancer.
[15] Cancer,et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.
[16] O. Brawley,et al. Introducing the 2010 American Cancer Society Prostate Cancer Screening Guideline , 2010, CA: a cancer journal for clinicians.
[17] D. Saslow,et al. Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening , 2010, CA: a cancer journal for clinicians.
[18] Antoinette M Stroup,et al. Prostate cancer early detection , 2010 .
[19] A. Miller,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[20] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[21] H. Nelson,et al. Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.
[22] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[23] L. Esserman,et al. Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.
[24] Harry J de Koning,et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). , 2009, European urology.
[25] Robert Simons,et al. American Cancer Society: Access to Care , 2008 .
[26] R. Flanigan,et al. Prostate specific antigen (PSA)‐based screening , 2008, International journal of urology : official journal of the Japanese Urological Association.
[27] Therese Miller,et al. Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.
[28] F. Hamdy,et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. , 2008, European urology.
[29] H. Klocker,et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality , 2008, BJU international.
[30] E. Halpern,et al. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. , 2007, Urology.
[31] Amy Blase,et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.
[32] Robert A Smith,et al. Cancer Screening in the United States, 2007: A Review of Current Guidelines, Practices, and Prospects , 2007, CA: a cancer journal for clinicians.
[33] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[34] A. D'Amico,et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. , 2006, The Journal of urology.
[35] J. Hugosson,et al. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. , 2005, Archives of internal medicine.
[36] L. Holmberg,et al. Natural history of early, localized prostate cancer. , 2004, JAMA.
[37] A. Partin,et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. , 2003, Urology.
[38] A. Méjean,et al. Dépistage du cancer de la prostate , 2003 .
[39] A. Miller. Screening for breast cancer with mammography , 2001, The Lancet.
[40] J. Moul,et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. , 2000, The Journal of urology.
[41] A. Horan,et al. Mean time to cancer‐specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate‐specific antigen screening and ablative therapy , 2000, BJU international.
[42] F. Schröder,et al. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction , 1999, The Prostate.
[43] F. Labrie,et al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.
[44] P. Glasziou,et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. , 1998, BMJ.
[45] J. Moul,et al. Age-specific reference ranges for serum prostate-specific antigen in black men. , 1996, The New England journal of medicine.
[46] S. Woolf. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.
[47] Thl. AGE-SPECIFIC REFERENCE RANGES FOR PROSTATE-SPECIFIC ANTIGEN. , 1993 .
[48] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[49] T. Stamey,et al. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .
[50] K. Markou,et al. National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .
[51] M. Wirth,et al. [European Association of Urology. Position statement on screening for prostate cancer]. , 2010, Actas urologicas espanolas.
[52] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[53] A. Moore,et al. Prostate cancer screening in New Zealand , 2004 .
[54] A. Villers,et al. [Prostate cancer screening]. , 2003, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[55] E. Feuer,et al. Impact of screening on incidence and mortality of prostate cancer in the United States. , 2001, Epidemiologic reviews.
[56] A. Partin,et al. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. , 1999, Urology.